Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.APP Pharmaceuticals, a subsidiary of Fresenius Kabi Pharmaceuticals, has increased the availability of its drugs including APP Diprivan (propofol 1%) and APP Propofol 1% (generic Diprivan).
Subscribe to our email newsletter
The company is said to have increased the production to supply the US market and meet the clinical needs of health care professionals.
Propofol, marketed under the brand name, Diprivan, is a fast-onset sedative-hypnotic agent used for the induction and maintenance of anesthesia or sedation.
APP Pharmaceuticals president and CEO John Ducker said in order to maintain a consistent supply of this drug, the company has responded promptly in the face of drug shortages to meet market demand.